Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0D7GE
|
||||
Former ID |
DIB000911
|
||||
Drug Name |
TAK-029
|
||||
Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Discontinued in Phase 1 | [545841] | ||
Company |
Takeda Pharmaceutical Co Ltd
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
[C@H]1(N(C(=O)CNC(=O)c2ccc(C(=N)N)cc2)CCN(C1=O)CC(=O)O)<br />CC(=O)OC
|
||||
CAS Number |
CAS 176655-58-6
|
||||
Target and Pathway | |||||
Target(s) | Glycoprotein IIb/IIIa receptor | Target Info | Modulator | ||
Reactome | Platelet degranulation | ||||
Elastic fibre formation | |||||
PECAM1 interactions | |||||
Molecules associated with elastic fibres | |||||
Integrin cell surface interactions | |||||
Syndecan interactions | |||||
ECM proteoglycans | |||||
Integrin alphaIIb beta3 signaling | |||||
GRB2:SOS provides linkage to MAPK signaling for Integrins | |||||
p130Cas linkage to MAPK signaling for integrins | |||||
VEGFA-VEGFR2 Pathway | |||||
MAP2K and MAPK activation | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.